Market Overview

UPDATE: Credit Suisse Assumes Coverage on Quest Diagnostics with Neutral Rating, $67 PT

Share:
Related DGX
Fast Money Picks For July 28
Earnings Scheduled For July 23, 2015

In a report published Friday, Credit Suisse assumed coverage on Quest Diagnostics (NYSE: DGX) with a Neutral rating and $67.00 price target.

Credit Suisse noted, “We are assuming coverage of DGX with a Neutral rating (previously Outperform). Recall DGX is the largest independent clinical laboratory in the U.S. We acknowledge the company & new management have an opportunity to offset some of the anemic top-line trends and close the margin gap relative to LH which could aid the earnings growth profile. Moreover strong cash flows & greater clarity this fall on plans to return value to shareholders should support valuation. However, trading at 12.4x our new F13 estimates on a P/E basis and 7.8x on an EV/EBITDA basis, and having outperformed industry & healthcare services peers YTD, we believe the current risk/reward profile is more balanced. We are increasing our estimates and maintaining our TP of $67.”

Quest Diagnostics closed on Thursday at $62.19.

Latest Ratings for DGX

DateFirmActionFromTo
Jun 2015Goldman SachsDowngradesBuyNeutral
Jun 2015KeyBancInitiates Coverage onSector Weight
Mar 2015JMP SecuritiesInitiates Coverage onMarket Perform

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Analyst Ratings

 

Related Articles (DGX)

Get Benzinga's Newsletters